Legislation & Regulation

AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.

Press Release: The Academy of Managed Care Pharmacy (AMCP) commends the House for its passage yesterday of H.R. 2430, the Food and Drug Administration Reauthorization Act (FDARA) of 2017. H.R. 2430 reauthorizes FDA’s critical user fee programs.

Press Release: The U.S. House Energy and Commerce Committee’s Subcommittee on Health held a hearing today on the “Pharmaceutical Information Exchange (PIE) Act of 2017” (H.R. 2026).

Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, comments on today's unanimous vote by the House Energy & Commerce (E&C) Committee to approve legislation reauthorizing the FDA’s user fee programs.

The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4472 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists. We strongly support the language in the Bill that allows a pharmacist to substitute an FDA approved “interchangeable biological product.”

AMCP CEO Blog: Whoever said, “May you live in interesting times,” could have been talking about Congressional health care policy debates circa 2017. Never a dull moment!